first line maintenance therapy

March 20, 2020March 20, 2020

China Reviewing Zejula as First-line Therapy for Ovarian Cancer

News

The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) be approved as first-line maintenance therapy for women with ovarian cancer who are responding to ... Read more

October 30, 2019October 30, 2019

Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows

News

Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase ... Read more

July 22, 2019August 26, 2019

Zejula Maintenance Therapy Extends Progression-free Survival in Advanced Ovarian Cancer Patients, Phase 3 Trial Shows

News

Maintenance treatment with Zejula (niraparib) extended the time without disease worsening in women with advanced ovarian cancer who had responded to first-line chemotherapy, according to updated results of a Phase ... Read more

July 16, 2018

Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), a PARP inhibitor, significantly prevents ovarian cancer from progressing or returning in women who responded to their first-line chemotherapy treatment, results from a Phase 3 trial show. The randomized, ... Read more